Wall Street brokerages predict that OncoCyte Corporation (NASDAQ:OCX) will post earnings per share of ($0.10) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for OncoCyte’s earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.11). OncoCyte reported earnings of ($0.12) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 16.7%. The firm is scheduled to report its next quarterly earnings results on Tuesday, May 21st.
On average, analysts expect that OncoCyte will report full year earnings of ($0.38) per share for the current fiscal year, with EPS estimates ranging from ($0.44) to ($0.31). For the next financial year, analysts forecast that the company will report earnings of ($0.46) per share, with EPS estimates ranging from ($0.54) to ($0.38). Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow OncoCyte.
OncoCyte (NASDAQ:OCX) last released its earnings results on Monday, April 1st. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.02).
Separately, Chardan Capital reiterated a “buy” rating on shares of OncoCyte in a research report on Tuesday, April 2nd.
NASDAQ OCX traded up $0.03 on Friday, hitting $4.33. 76,942 shares of the company’s stock were exchanged, compared to its average volume of 1,068,737. OncoCyte has a fifty-two week low of $1.16 and a fifty-two week high of $6.92.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Read More: Coverage Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.